Quarterly ResultMay 12, 2026, 04:23 PM
TherapeuticsMD Swings to Q1 Net Income of $95K; Revenue Up 84%
AI Summary
TherapeuticsMD, Inc. reported a significant financial turnaround in Q1 2026, achieving a net income of $95 thousand compared to a net loss of $653 thousand in the prior year. This improvement was driven by an 84.2% increase in license revenue to $724 thousand. The company, which transitioned to a pharmaceutical royalty model, continues to face substantial legal challenges, including ongoing lawsuits with Mayne Pharma regarding working capital adjustments and an IMVEXXY patent infringement case, leading to a going concern warning.
Key Highlights
- Reported net income of $95 thousand for Q1 2026, a significant improvement from a net loss of $653 thousand in Q1 2025.
- License revenue increased to $724 thousand in Q1 2026, up 84.2% from $393 thousand in Q1 2025.
- Cash and cash equivalents rose to $8.419 million as of March 31, 2026, from $7.483 million at December 31, 2025.
- Net cash provided by continuing operating activities was $944 thousand in Q1 2026, up from $699 thousand in Q1 2025.
- Filed a lawsuit against Mayne Pharma on April 8, 2025, for breach of contract related to net working capital allowances.
- Mayne Pharma filed a countersuit on May 30, 2025, for breach of contract and fraudulent inducement.
- A magistrate judge recommended partial dismissal of both Mayne Lawsuits and a stay for dispute resolution on March 23, 2026.
- Capitalized $2.334 million in legal costs for the ongoing IMVEXXY patent infringement lawsuit against Teva Pharmaceuticals.